Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy CAMBRIDGE, Mass. , March 22, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and